Pacritinib · VEXAS Syndrome (PAXIS)
Enrollment reopened
Swedish Orphan BiovitrumPhase 2 NCT06782373 Registry history of NCT06782373 on ClinicalTrials.gov (opens the registry)
4 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 3 with minor changes only.
Enrollment reopened
Swedish Orphan BiovitrumPhase 2 NCT06782373 Registry history of NCT06782373 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 89 participants (planned 104)
Swedish Orphan BiovitrumPhase 3 NCT06716814 Registry history of NCT06716814 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Swedish Orphan BiovitrumPhase 4 NCT06940830 Registry history of NCT06940830 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jul 2026 to May 4, 2026
Swedish Orphan BiovitrumNot specified NCT04293523 Registry history of NCT04293523 on ClinicalTrials.gov (opens the registry)
| Phase 2 | 1 | |
| Phase 2/3 | 1 | |
| Phase 3 | 3 | |
| Phase 4 | 3 |
Hemophilia (3) · Myelofibrosis (2) · Myelodysplastic Syndromes (MDS) (1) · Rheumatoid Arthritis (1)